Aptevo Therapeutics secures warrant exercise agreements for $3 million in gross proceeds
APVO•Aptevo Therapeutics expects to raise approximately $3 million from cash exercises of warrants covering 2,777,778 shares at $1.08 each. Holders will receive new warrants for 13,888,890 shares at the same exercise price, and the transaction is expected to close around November 12, 2026.
1. Warrant agreements
Aptevo Therapeutics secured agreements for cash exercises of existing common warrants covering 2,777,778 shares at a reduced exercise price of $1.08 per share, generating expected gross proceeds of approximately $3 million. In exchange, holders will receive new unregistered warrants to purchase 13,888,890 shares at $1.08 per share.
2. Approval and proceeds
The new warrants become exercisable upon required stockholder approval and expire five years after their initial exercise date. The transaction is expected to close around November 12, 2026, subject to customary conditions, and net proceeds will fund working capital.
